Department of Pharmacy Practice, SRM College of Pharmacy, SRM IST, Kattankulathur, 603203, Kancheepuram, Tamil Nadu, India.
Sree Balaji Medical College and Hospital, Chennai, Tamil Nadu, 600044, India.
Diabetes Metab Syndr. 2022 Mar;16(3):102451. doi: 10.1016/j.dsx.2022.102451. Epub 2022 Mar 7.
This Review discusses the potential drug interactions risk between Drugs used in treating COVID-19 infection and Drugs used in treating comorbid conditions (Diabetes, hypertension, cardiovascular illness).
Six Databases were consulted a) Micromedex drug interaction b) Medicine complete.com c) Liverpool Drug Interaction Group for COVID-19 therapies d) Epocrates e) Medscape f) drugs.com. To acquire information on possible interaction effects between drugs used for COVID-19 treatment such as atazanavir, lopinavir/ritonavir, remdesivir, molnupiravir, paxlovid(nirmatrelvir/ritonavir), dexamethasone, azithromycin, chloroquine, and FDA approved monoclonal antibodies with primarily used antidiabetic drugs, antihypertensive drugs, and drugs acting on the cardiovascular system.
Potential interaction effects such as worsening glycemic control were prominent with lopinavir/ritonavir and the primarily used antidiabetic drugs, which needs dosage adjustment and close monitoring. The risk of hypotension and irregular heart rhythm is the potential interaction effects with concomitant use of drugs for COVID-19 treatment and antihypertensive drugs. Caution is advised with drugs such as atazanavir and lopinavir/ritonavir when concomitantly used in treating comorbid conditions. Drugs such as remdesivir, molnupiravir, and some monoclonal antibodies are safer in use with drugs used in treating the comorbid condition.
Drug-drug interaction remains one of the significant factors in altering the therapeutic efficacy. Drugs used to manage comorbid conditions may influence the COVID-19 treatment with potential interaction effects. These enhance the view on safety concerns about the drug interaction risk in managing COVID-19 infection in patients with comorbid conditions. This primary evidence may concern preventing potential or unintentional effects resulting from Drug-drug interaction, Improving patient quality of life.
本综述讨论了治疗 COVID-19 感染的药物与治疗合并症(糖尿病、高血压、心血管疾病)的药物之间潜在的药物相互作用风险。
共检索了 6 个数据库,包括 a)Micromedex 药物相互作用数据库、b)Medicine complete.com、c)利物浦 COVID-19 治疗药物相互作用组、d)Epocrates、e)Medscape 和 f)drugs.com,以获取有关治疗 COVID-19 的药物(如阿扎那韦、洛匹那韦/利托那韦、瑞德西韦、莫努匹韦、帕罗维德(奈玛特韦/利托那韦)、地塞米松、阿奇霉素、氯喹和 FDA 批准的单克隆抗体)与主要用于治疗糖尿病、高血压和心血管系统疾病的药物之间可能发生的相互作用的信息。
洛匹那韦/利托那韦和主要用于治疗糖尿病的药物合用会导致血糖控制恶化等明显的相互作用,需要调整剂量并密切监测。同时使用 COVID-19 治疗药物和降压药物会导致低血压和心律失常等潜在的相互作用。在治疗合并症时,应谨慎使用阿扎那韦和洛匹那韦/利托那韦等药物。瑞德西韦、莫努匹韦和一些单克隆抗体与治疗合并症的药物一起使用更安全。
药物相互作用仍然是改变治疗效果的重要因素之一。用于治疗合并症的药物可能会影响 COVID-19 的治疗效果,并可能产生潜在的相互作用。这些增强了对管理合并症 COVID-19 感染时药物相互作用风险的安全性关注。这种主要证据可能涉及预防药物相互作用引起的潜在或非故意影响,提高患者的生活质量。